Royal Papworth Hospital NHS Foundation Trust.

Cambridge CB23 3RE

4 studies enrolling now · 17 studies all time

What they study most

Acute Myocardial Infarction, Atrial Fibrillation, Bleeding, Bronchiolitis Obliterans, Bronchiolitis Obliterans Syndrome, Cardiac Surgery, Chronic Lung Allograft Dysfunction, Chronic Rejection of Lung Transplant, Cystic Fibrosis, Disorder, Heart, Heart Failure

Studies at this site

• An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) — Recruiting now
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) — Recruiting now
• Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG — Recruiting now
• Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery — Recruiting now
• Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH) — Running, not enrolling
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy — Running, not enrolling
• A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing — Completed
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) — Completed
• Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) — Stopped early
• A Study of Ponsegromab in People With Heart Failure — Stopped early
• Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF — Completed
• Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) — Completed
• A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease — Completed
• A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) — Completed
• A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation — Completed
• Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis — Completed